Tech Transfer Roundup: UCSD Sees Many Benefits From Entrepreneurs In Residence Program
Executive Summary
Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.
You may also be interested in...
Herantis Awaits CDNF Results This Year In Parkinson's Disease
Executive Interview: Reducing “ER stress” is one of the potential mechanisms of action of a novel candidate Parkinson’s agent being evaluated by Finland’s Herantis, which completed an additional stock market listing, in Sweden, last month.
Tech Transfer Roundup: Trio Of Deals Bolster Spherix’s Cancer Strategy
The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.
Akero Shows FGF21/GLP-1 Combo’s Potential In NASH And Type 2 Diabetes
Phase IIb data show that Akero’s efruxifermin on top of GLP-1 therapy is relatively safe and offers liver fat reductions and fibrosis improvements in NASH patients with type 2 diabetes.